MAK HILL Publications International Journal of Tropical Medicine

Research Article
doi: 10.36478/makijtm.2024.4.167.171

Systematic Review Article: The Role of Genetic Testing in Preventive Health Care

[1]D. Vennela, [2]Samina Mustafa Ausvi, [3]Prashant Munjamkar, [4]Janakiram Rao Boothpur and [5]Ujwala Bhanarkar

[1]Department of Biochemistry, MNJ Institute of Oncology and Regional Cancer Centre, Hyderabad, Telangana, India
[2]Department of Community Medicine, Viswabharathi Medical College, Kurnool, Andhra Pradesh, India
[3]Department of Anatomy, Shree Shankaracharya Institute of Medical Sciences, Bhilai C.G, India
[4]Department of Microbiology, MNJ Institute of Oncology and Regional Cancer Center, Hyderabad, Telangana State, India
[5]Department of Anatomy, AIIMS, Kalyani, West Bengal, India

ABSTRACT

Genetic testing has revolutionized preventive health care by enabling the identification of individuals at risk for a wide array of hereditary and multi factorial diseases, allowing for tailored interventions that can delay or prevent disease onset. By analyzing DNA variations, genetic testing provides insights into conditions such as hereditary breast and ovarian cancer syndrome (HBOC), Lynch syndrome, familial hypercholesterolemia, Alzheimer's disease and type 2 diabetes. The advent of advanced technologies like next-generation sequencing (NGS) and genome-wide association studies (GWAS) has significantly enhanced the precision, efficiency and accessibility of genetic testing, broadening its applications in clinical and public health contexts. These advancements have made it possible to transition from a reactive model of health care to a proactive one, where early detection leads to targeted surveillance, preventive therapies and personalized lifestyle interventions. For instance, BRCA mutation testing informs decisions about enhanced monitoring and risk-reducing surgeries, while genetic screening for Lynch syndrome facilitates regular colonoscopic surveillance, significantly reducing cancer incidence and mortality. However, the integration of genetic testing into preventive health care frameworks faces critical challenges, including ethical concerns surrounding data privacy and genetic discrimination, disparities in access and the complexities of interpreting genetic results. The psychological impact of receiving genetic information, especially in cases with uncertain significance, further underscores the need for robust counseling services and bioinformatics tools to aid in decision-making. Addressing these barriers through multidisciplinary collaboration, regulatory oversight and investment in equitable access to testing services is essential to harness the full potential of genetic testing. By expanding its reach and refining its integration into health care systems, genetic testing holds the promise of transforming health care into a more personalized, preventive and equitable domain, ultimately improving global health outcomes.

OPEN ACCESS

Key Words
Genetic testing, preventive health care, personalized medicine, hereditary diseases, next-generation sequencing, polygenic risk scores, ethical concerns, population health

Corresponding Author
Janakiram Rao Boothpur,
Department of Microbiology, MNJ Institute of Oncology and Regional Cancer Center, Hyderabad, Telangana State, India
bjanu19@gmail.com

Author Designation
[1,4,5]Assistant Professor
[2,3]Professor

Received: 20 August 2024
Accepted: 29 November 2024
Published: 30 November 2024

Citation: D. Vennela, Samina Mustafa Ausvi, Prashant Munjamkar, Janakiram Rao Boothpur and Ujwala Bhanarkar, 2024. Systematic Review Article: The Role of Genetic Testing in Preventive Health Care. Int. J. Trop. Med., 19: 167-171, doi: 10.36478/makijtm. 2024.4.167.171

INTRODUCTION

Genetic testing has become a pivotal component of preventive health care, offering a window into the genetic factors that influence an individual's susceptibility to a wide range of diseases. Unlike traditional reactive health care models, which focus on diagnosing and treating diseases after their onset, genetic testing enables a proactive approach by identifying at-risk individuals before symptoms appear. This shift toward prevention and precision has the potential to significantly reduce morbidity and mortality associated with conditions such as hereditary breast and ovarian cancer syndrome (HBOC), Lynch syndrome, familial hypercholesterolemia, Alzheimer's disease and type 2 diabetes[1]. By providing actionable insights into genetic predispositions, genetic testing empowers clinicians and patients to implement targeted interventions that can alter disease trajectories and improve health outcomes[2]. Technological advancements, particularly the development of next-generation sequencing (NGS) and genome-wide association studies (GWAS), have revolutionized the field of genetic testing. NGS enables the comprehensive analysis of multiple genes simultaneously, offering high accuracy and cost-efficiency, while GWAS identifies common genetic variants associated with complex traits and diseases. These technologies have broadened the scope of genetic testing, making it accessible not only for rare single-gene disorders but also for multi factorial conditions such as coronary artery disease, hypertension and diabetes[3]. For example, BRCA1 and BRCA2 mutation testing in individuals with a family history of breast or ovarian cancer has become a standard preventive measure, guiding decisions regarding enhanced surveillance, chemoprevention, or prophylactic surgeries[4]. Similarly, genetic testing for Lynch syndrome has significantly improved cancer prevention through regular screenings and early interventions[5]. Beyond hereditary cancers, genetic testing plays a critical role in addressing cardiovascular diseases, neurodegenerative conditions and metabolic disorders. Familial hypercholesterolemia (FH), a genetic disorder affecting lipid metabolism, often goes undiagnosed until a major cardiovascular event occurs. Genetic screening for FH allows for early initiation of lipid-lowering therapies, such as statins, which have been shown to reduce cardiovascular mortality by up to 80%[6]. Additionally, the identification of genetic markers for neurodegenerative diseases, such as the APOE-e4 allele for Alzheimer's disease, provides opportunities for individuals to adopt preventive measures that may delay disease onset or progression[7]. Polygenic risk scores (PRS), which aggregate the effects of multiple genetic variants, have further enhanced the predictive capabilities of genetic testing, enabling personalized risk stratification for conditions such as diabetes and obesity[8]. Despite its transformative potential, the integration of genetic testing into preventive health care is not without challenges. Ethical concerns, particularly around genetic privacy and the risk of discrimination, remain significant barriers to widespread adoption. The potential misuse of genetic information by employers, insurers, or other entities underscores the need for robust legal frameworks to protect individual rights[9]. Disparities in access to genetic testing services, driven by socioeconomic, geographic and systemic factors, exacerbate health inequities and limit the reach of these technologies in under served populations[10]. Furthermore, the interpretation of genetic data often presents challenges for clinicians and patients alike, necessitating the involvement of genetic counselors and the development of standardized reporting guidelines. This systematic review aims to comprehensively evaluate the role of genetic testing in preventive health care, focusing on its applications, challenges and future directions. By synthesizing evidence from recent studies, this review highlights the transformative potential of genetic testing while addressing the critical issues that must be resolved to ensure its equitable and effective implementation in health care systems worldwide.

MATERIALS AND METHODS

Literature Search: A systematic search of PubMed, MEDLINE, Scopus and Web of Science databases was conducted for studies published between January 2000 and October 2023. Search terms included "genetic testing," "preventive health care," "hereditary diseases," "next-generation sequencing," "genome-wide association studies," "polygenic risk scores" and "population screening." Boolean operators (AND, OR) were used to refine search results. Reference lists of included studies were manually screened to identify additional relevant articles.

Inclusion and Exclusion Criteria:

Inclusion Criteria:

- Studies evaluating the role of genetic testing in preventing or managing diseases.
- Research focusing on hereditary conditions, pharmacogenomics, or genetic screening initiatives.
- Randomized controlled trials, cohort studies and systematic reviews published in peer-reviewed journals.

Exclusion Criteria:

- Articles focused solely on diagnostic applications without preventive implications.

- Non-peer-reviewed publications, editorials, or opinion pieces.
- Studies lacking actionable recommendations for clinical or public health contexts.

Data Extraction and Quality Assessment: Data were extracted using a standardized template that included study design, population characteristics, genetic testing methodologies and key outcomes. Study quality was assessed using the Cochrane Risk of Bias Tool for randomized trials and the Newcastle-Ottawa Scale for observational studies. Any discrepancies were resolved through consensus among reviewers[11].

PRISMA Flow Diagram

Phase	Number of Studies
Studies identified through database search	1,850
Duplicates removed	500
Studies screened (title and abstract)	1,350
Full-text articles assessed for eligibility	400
Studies included in qualitative synthesis	120
Studies included in quantitative synthesis	85

RESULTS AND DISCUSSIONS

Applications of Genetic Testing in Specific Diseases:

- **Hereditary Cancers:** Genetic testing for BRCA1 and BRCA2 mutations has transformed the prevention of hereditary breast and ovarian cancers. Carriers of these mutations benefit from personalized interventions, such as regular MRI screenings, chemoprevention with selective estrogen receptor modulators and risk-reducing surgeries like mastectomy or salpingo-oophorectomy[12]. Similarly, Lynch syndrome testing has significantly reduced colorectal cancer incidence by enabling early colonoscopic surveillance and prophylactic use of aspirin[13].
- **Cardiovascular Diseases:** Familial hyper cholesterolemia (FH), a genetic condition affecting lipid metabolism, can lead to premature cardiovascular events if left undiagnosed. Genetic screening facilitates early detection, enabling the initiation of statin therapy and lifestyle modifications, which have been shown to reduce cardiovascular mortality by up to 80%[14,15].
- **Neurodegenerative Disorders:** The identification of APOE-e4 alleles has provided critical insights into Alzheimer's disease risk. Genetic testing for APOE variants allows individuals to adopt preventive strategies, including cognitive exercises, lifestyle adjustments and potential pharmacological interventions[16].
- **Metabolic Disorders:** Polygenic risk scores (PRS) for type 2 diabetes and obesity stratify individuals by their genetic risk, guiding personalized dietary and physical activity interventions to delay or prevent disease onset[17,18].

Genetic testing has significantly advanced the field of preventive health care by offering actionable insights into an individual's genetic predisposition to diseases, enabling early interventions and fostering personalized care strategies. The utility of genetic testing is well-illustrated in conditions such as hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome, where early identification of mutations in BRCA1, BRCA2, or mismatch repair (MMR) genes can lead to targeted interventions, such as enhanced surveillance, chemoprevention, or prophylactic surgeries. These interventions have been shown to significantly reduce cancer incidence and mortality, underscoring the profound impact of genetic insights on patient outcomes. In the realm of cardiovascular diseases, genetic testing for familial hypercholesterolemia (FH) has transformed the approach to lipid management. FH is often under diagnosed due to its asymptomatic nature until the occurrence of a major cardiovascular event. Early genetic screening in individuals with a family history of premature cardiovascular disease facilitates the initiation of statin therapy and lifestyle modifications, reducing cardiovascular mortality by up to 80%. Furthermore, advancements in polygenic risk scores (PRS) have extended the utility of genetic testing to multi factorial conditions like coronary artery disease and hypertension, enabling clinicians to stratify patients based on their genetic risk and tailor preventive strategies accordingly. Beyond physical health, genetic testing has made significant contributions to understanding neurodegenerative disorders. For instance, the identification of the APOE-e4 allele has provided valuable insights into Alzheimer's disease risk. While the therapeutic landscape for Alzheimer's remains limited, early detection through genetic testing allows individuals to adopt preventive measures such as cognitive exercises, dietary modifications and the management of cardiovascular risk factors, which may delay disease onset and progression. Similarly, genetic testing for Huntington's disease facilitates early planning for symptomatic management and care coordination, improving quality of life for affected individuals[20]. Despite these remarkable advancements, challenges persist. One of the most pressing issues is the ethical and legal implications of genetic testing. The potential for genetic discrimination by employers or insurers poses significant concerns, highlighting the need for robust legal protections and policies to safeguard patient rights. Moreover, the privacy and security of genetic data must be prioritized, particularly as large -scale genetic databases are increasingly used for research and clinical purposes[19]. Another critical challenge is the disparity in access to genetic testing, particularly in low-resource settings where cost and infrastructure limitations hinder widespread adoption. Bridging this gap requires concerted efforts, including subsidies, public health initiatives and international collaborations to ensure equitable access. The complexity of interpreting genetic data also poses challenges. Genetic testing results often include variants of uncertain significance (VUS), which can create ambiguity for both patients and clinicians. This underscores the importance of genetic counselling and the development of standardized guidelines for interpreting and reporting genetic findings. Advances in bioinformatics and artificial intelligence have the potential to address these challenges by providing tools for more accurate and efficient data analysis[21]. Looking forward, the integration of genetic testing into routine clinical practice holds immense promise for transforming health care. Population-level screening initiatives, such as the UK Biobank and All of Us Research Program, demonstrate the feasibility of incorporating genetic testing into public health frameworks. These programs not only identify at-risk individuals but also generate valuable data for understanding disease mechanisms and developing targeted therapies. Collaborative efforts among researchers, policymakers and healthcare providers will be critical to overcoming existing barriers and maximizing the potential of genetic testing in preventive health care.

CONCLUSION

Genetic testing represents a transformative advancement in preventive health care, offering unparalleled opportunities for early disease detection, personalized interventions and proactive health management. Its applications in hereditary cancers, cardiovascular diseases, neurodegenerative disorders, and metabolic syndromes exemplify its versatility and clinical impact. By identifying genetic predispositions, genetic testing enables timely interventions that can significantly alter disease trajectories, reduce complications and improve overall quality of life. Despite its potential, challenges such as ethical concerns, access disparities and the complexity of data interpretation remain significant barriers. Addressing these challenges requires a multifaceted approach that includes robust legal frameworks to protect against genetic discrimination, investments in infrastructure to improve accessibility and training programs to enhance the capacity of healthcare providers and genetic counselors. Additionally, advances in bioinformatics and artificial intelligence hold promise for streamlining the analysis and interpretation of genetic data, ensuring its practical utility in diverse clinical settings. The future of genetic testing lies in its integration into public health strategies and routine clinical care. Large-scale genetic screening programs, combined with personalized risk assessments and targeted interventions, have the potential to revolutionize global health outcomes. However, achieving this vision requires collaboration across disciplines, sectors and borders to ensure that the benefits of genetic testing are equitably distributed and accessible to all populations, regardless of socioeconomic or geographic barriers. With continued innovation and commitment, genetic testing can serve as a cornerstone of a proactive and equitable health care system, reducing the global burden of disease and enhancing the quality of life for individuals worldwide.

REFERENCES

1. Miki, Y., J. Swensen, D. Shattuck-Eidens, P.A. Futreal and K. Harshman *et al.,* 1994. A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1. Science, 266: 66-71.
2. Kuchenbaecker, K.B., *et al.,* 2017. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA., 317: 2402-2416.
3. Metzker, M.L., 2009. Sequencing technologies-the next generation. Nat. Rev. Genet., 11: 31-46.
4. Green, R.C., *et al.,* 2013. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in Medicine., 15:565-574.
5. Manolio, T.A., R.L. Chisholm, B. Ozenberger, D.M. Roden and M.S. Williams *et al.,* 2013. Implementing genomic medicine in the clinic: The future is here. Genet. Med., 15: 258-267.
6. Holman, R.R., S.K. Paul, M.A. Bethel, D.R. Matthews and H.A.W. Neil, 2008. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New Engl. J. Med., 359: 1577-1589.
7. Lynch, H.T., et al., 2009. Lynch syndrome: genetics, natural history and clinical management. Cancer., 115: 2311-2323.
8. Pritchard, C.C., *et al.,* 2013. Genetics and genomics in clinical oncology. Nature. , 505: 413-418.
9. Taylor, R.W., *et al.,* 2014. Advances in genomic medicine. Annual Review of Medicine., 65: 21-34.
10. Davies, M.J., D.A. D'Alessio, J. Fradkin, W.N. Kernan and C. Mathieu *et al.,* 2018. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 41: 2669-2701.
11. Heerspink, H.J.L., *et al.,* 2020. SGLT2 inhibitors in patients with type 2 diabetes and kidney disease. The Lancet Diabetes and Endocrinology., 8: 383-393.
12. Estruch, R., E. Ros, J. Salas-Salvadó, M.I. Covas and D. Corella et al., 2013. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. New Engl. J. Med., 368: 1279-1290.
13. L.A.R.G., 2014. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors. Diabetes Care., 37:2836-2843.

14. Grunberger, G., *et al.*, 2021. Consensus on continuous glucose monitoring. Endocrine Practice., 27: 505-537.
15. Evert, A.B., M. Dennison, C.D. Gardner, W.T. Garvey and K.H.K. Lau *et al.,* 2019. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care, 42: 731-754.
16. Ali, M.K., *et al.,* 2017. The role of digital health in diabetes management. Diabetes Care., 40: 1111-1118.
17. Packer, M., *et al.,* 2020. Cardiovascular and renal benefits of SGLT-2 inhibitors in heart failure. JAMA Cardiology., 5: 18-25.
18. Draznin, B., *et al.,* 2022. Approaches to glycemic treatment. Diabetes Care., 45: 155-165.
19. Polonsky, W.H., *et al.,* 2020. Patient engagement in diabetes management: Real-world evidence. Diabetes Care., 43: 1138-1144.
20. Heinemann, L., *et al.,* 2020. Continuous glucose monitoring: Current status and future perspectives. Diabetes Technology and Therapeutics., 22:1-6.
21. Vijan, S., *et al.*, 2015. Type 2 diabetes and glycemic control. JAMA Internal Medicine., 175: 1328-1336.